,molecule,cas,best_match_url,results,query_url,query_type,Highest Development Event Status and Year,Highest Development Event Source ID,Highest Development Event Source URL,Earliest Approved Event Status and Year,Earliest Approved Event Source ID,Earliest Approved Event Source URL,conditions,phases
1,ALPHA AMYLASE,1109-28-0,https://drugs.ncats.io/drug/639K0T34IK,1,"https://drugs.ncats.io/substances?q=(root_codes_CAS:""1109%2028%200"")",ONLY CAS,,,,,,,,
13,DOLOMITE,7000-29-5,https://drugs.ncats.io/drug/UG9H2002BF,1,"https://drugs.ncats.io/substances?q=(root_codes_CAS:""7000%2029%205"")",ONLY CAS,Clinical 2013,NCT01831492: Not Applicable Interventional Completed Acidosis,https://clinicaltrials.gov/ct2/show/NCT01831492,,,,Unknown,
22,FURAZOLIDONE,67-45-8,https://drugs.ncats.io/drug/5J9CPU3RE0,1,"https://drugs.ncats.io/substances?q=(root_codes_CAS:""67%2045%208"")",ONLY CAS,US Previously Marketed 1961,FUROXONE by SHIRE,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011270,US Previously Marketed 1957,Tricofuron by Eaton,OB NME Appendix 1950-1985,Bacterial or protozoal enteritis; Bacterial or protozoal diarrhea,Approved; Approved
46,NABILONE,51022-71-0,https://drugs.ncats.io/drug/2N4O9L084N,1,"https://drugs.ncats.io/substances?q=(root_codes_CAS:""51022%2071%200"")",ONLY CAS,US Approved Rx 1985,NDA018677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018677,US Approved Rx 1985,NDA018677,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018677,Nausea and vomiting,Approved
72,TALAZOPARIB,1373431-65-2,https://drugs.ncats.io/drug/02WK9U5NZC,1,"https://drugs.ncats.io/substances?q=(root_codes_CAS:""1373431%2065%202"")",ONLY CAS,US Approved Rx 2018,NDA211651,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,US Approved Rx 2018,NDA211651,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,Unknown; Ovarian cancer; Breast cancer,Phase III; Approved
77,VITAMIN F,506-32-1,https://drugs.ncats.io/drug/27YG812J1I,1,"https://drugs.ncats.io/substances?q=(root_codes_CAS:""506%2032%201"")",ONLY CAS,Possibly Marketed Outside US 2013,LipoGel CR Base by Southeastern Medical Technologies,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f46f213-36aa-4cb6-8c6d-2bf94de1387e,Possibly Marketed Outside US 2013,LipoGel CR Base by Southeastern Medical Technologies,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f46f213-36aa-4cb6-8c6d-2bf94de1387e,,
